entertainment -WSS

entertainment

author：hotspot 2025-09-27 09:54:24 - browse：24589

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Humana cuts profit projections as Medicare Advantage costs soar

hotspot

WSS

My yearlong odyssey to get my son’s ADHD medication covered

Test for long Covid? Researchers find new clue in blood samples

Insmed lung disease drug hits target in key Phase 3 trial

Francis Collins on trust in science and how Covid communications failed

Akili, maker of video game for ADHD, to be acquired for 34 million

Focused ultrasound for uterine fibroids: an uphill battle

hotspot

entertainment

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Merck, J&J, and long Covid

How one medical school became remarkably diverse

AI used to predict Covid

How one medical school became remarkably diverse

Heat waves linked to early deliveries, preterm births in new study

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

David Sabatini, ex

What does generative AI mean for health care? We asked experts

Average age of first period drops to 11.9 years, study shows

leisure time

Health insurers say they are turning to AI to cut costs, improve care

Why doctors need education on FDA device approval process

Francis Collins on trust in science and how Covid communications failed

Independent physicians launch a new lobbying group

Eli Lilly, Pfizer, and others want in on the online prescription market

Eli Lilly, Pfizer, and others want in on the online prescription market

focus

hotspot

leisure time

Wikipedia